Table 2.
Plan objectives and dosimetric results.
| Plan dosimetry | Plan objective | Median | mean | IQR |
|---|---|---|---|---|
| PTV | ||||
| D50% (Gy) | ≥45.0 | 46.6 | 46.6 | 46.4-46.7 |
| Dmean (Gy) | ≥45.0 | 45.8 | 45.8 | 45.6-46.0 |
| D95% (Gy) | ≥40.5 | 40.6 | 40.4 | 40.0-41.2 |
| D2% (Gy) | ≤48.2 | 47.9 | 47.9 | 47.8-48.1 |
| D98% (Gy) | ≥38.2 | 38.4 | 38.6 | 38.1-39.1 |
| V45Gy (%) | ≥80 | 80.6 | 80.8 | 77.7-84.0 |
| V40.5Gy (%) | ≥95 | 94.6 | 95.1 | 93.9-96.2 |
| Urethral wall | ||||
| D2% (Gy) | ≤40.5 | 38.7 | 38.8 | 38.4-39.2 |
| D1cm 3 (Gy) | ≤36.0 | 33.7 | 34.4 | 33.8-34.9 |
| Bladder | ||||
| D2% (Gy) | ≤40.5 | 36.8 | 37.5 | 28.2-40.6 |
| D5o% (Gy) | ≤22.5 | 14.5 | 10.5 | 8.0-12.4 |
| D1cm3 (Gy) | ≤40.5 | 38.6 | 38.9 | 38.2-39.5 |
| Rectal wall | ||||
| D2% (Gy) | ≤42.8 | 35.5 | 35.2 | 35.1-35.8 |
| D5% (Gy) | ≤40.5 | 32.7 | 33.3 | 32.2-33.8 |
| D5o% (Gy) | ≤22.5 | 9.9 | 14.4 | 7.27-17.6 |
| D1cm3 (Gy) | ≤36.0 | 35.6 | 35.3 | 35.0-35.5 |
| UGD | ||||
| D2% (Gy) | ≤42.8 | 35.9 | 37.4 | 33.3-39.7 |
| Penile bulb | ||||
| D2% (Gy) | ≤36.0 | 3.3 | 2.4 | 1.8-3.5 |
| D1cm (Gy) | ≤22.5 | 2.0 | 1.6 | 1.3-2.2 |
| NVBs | ||||
| D2% (Gy) | ≤45.0 | 39.6 | 41.4 | 39.0-44.6 |
| D5o% (Gy) | ≤31.5 | 30.1 | 31.3 | 28.5-33.8 |
| Femoral heads | ||||
| D2% (Gy) | ≤22.5 | 12.9 | 12.8 | 5.5-20.9 |
PTV, Planning Target Volume; Dmean. mean dose; D2%, D5%, D5o%D95%, D98%, minimum dose to n% of the structure; V458y, V40.58y, percentage of structure receiving 45Gy or 40.5Gy (100% and 90% of the prescription dose); D1cm3, dose to 1 cm3 of the structure; UGD, urogenital diaphragm; NVB, neurovascular bundles.